ALIVUS - Fundamental Analysis

Last Updated Time : 02 Aug 25, 12:58 am

Fundamental Rating: 3.1

Here’s a holistic assessment of ALIVUS — a mid-cap pharma player exhibiting premium valuation but with some notable data gaps that need cautious attention before investing.

📊 Core Financials Snapshot

EPS: ₹359 — appears strong on paper, but may reflect one-time income or accounting adjustments. Needs validation via consistent quarterly PAT figures (currently missing).

ROE & ROCE: Not reported — absence of these efficiency metrics makes return analysis incomplete.

PAT Data: Quarter-on-quarter profit not disclosed — unable to determine growth momentum or margin trends.

Debt-to-Equity Ratio: Not available — unclear leverage position.

🧮 Valuation Overview

Metric Value Interpretation

P/E Ratio 35.3 Slightly above Industry PE of 34 — priced for growth

P/B Ratio — Not available — unclear if valuation premium is justified

PEG Ratio — Missing — growth-adjusted valuation cannot be determined

Intrinsic Value Likely higher than peers Based on elevated EPS, but may lack sustainability confirmation

🧠 Business Model & Competitive Posture

Likely operating in specialty formulations or high-margin APIs, inferred from elevated EPS and dividend payout.

Dividend Yield: 2.21% — relatively attractive, suggests steady cash flows and shareholder focus.

Institutional sentiment

FII Holdings ↓ -0.15%

DII Holdings ↑ +0.43% — minor rebalancing, neutral implications.

📉 Technical & Sentiment Indicators

RSI: 44.6 — approaching oversold zone, opportunity for near-term accumulation.

MACD: -0.20 — weak bearish crossover, short-term caution warranted.

Trading just below DMA 50 & DMA 200 — hints at consolidation phase.

Price near ₹1,017, with support closer to ₹827 — attractive entry if positive earnings resume.

🧭 Suggested Strategy

Entry Zone: ₹980–₹1,010 — favorable technical setup for medium-term buyers.

Holding View

Neutral to mildly positive outlook based on past price trajectory and dividend signals.

Key to monitor: reinstatement of quarterly profits, ROE/ROCE disclosures, debt clarity.

Until more data becomes available, avoid aggressive allocation — treat as a watchlist candidate with a trailing stop.

If you'd like, I can help model a future valuation matrix assuming possible PAT growth rates and reversion to industry mean metrics. That could make the investment thesis more tangible 📐📈.

Edit in a page